#BEGIN_DRUGCARD DB01202

# AHFS_Codes:
28:12.92

# ATC_Codes:
N03AX14

# Absorption:
Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.

# Biotransformation:
The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected.

# Brand_Mixtures:
Not Available

# Brand_Names:
Keppra

# CAS_Registry_Number:
102767-28-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H14N2O2

# Chemical_IUPAC_Name:
(2R)-2-(2-oxopyrrolidin-1-yl)butanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2247028

# Description:
Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anticonvulsants
Nootropic Agents

# Drug_Interactions:
Carbamazepine	Concomitant therapy may results in additive adverse CNS effects.
Triprolidine	The CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Take without regard to meals. Food does not affect bioavailabilty.

# GenBank_ID:
Not Available

# Generic_Name:
Levetiracetam

# HET_ID:
Not Available

# Half_Life:
6-8 hours

# InChI_Identifier:
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

# InChI_Key:
InChIKey=HPHUVLMMVZITSG-ZCFIWIBFSA-N

# Indication:
Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

# KEGG_Compound_ID:
C07841

# KEGG_Drug_ID:
D00709

# LIMS_Drug_ID:
1202

# Mechanism_Of_Action:
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
170.209

# Molecular_Weight_Mono:
170.105527702

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/kep1561.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450206

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.64

# Predicted_LogS:
0.24

# Predicted_Water_Solubility:
2.98e+02 g/l

# Primary_Accession_No:
DB01202

# Protein_Binding:
Very low (<10%)

# PubChem_Compound_ID:
441341

# PubChem_Substance_ID:
46508406

# RxList_Link:
http://www.rxlist.com/cgi/generic3/keppra.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01068

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC[C@@H](N1CCCC1=O)C(N)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Levetiracetam [INN]
Levetiracetamum [INN-Latin]
Levitiracetam

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing

# Update_Date:
2013-02-08 16:20:00 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Levetiracetam

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic vesicle
multi-pass memb
secretory vesicle
synaptic vesicle
synaptic vesicle membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15210974	Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21.
15367040	Stahl SM: Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep;65(9):1162-3.
16434140	Lambeng N, Grossmann M, Chatelain P, Fuks B: Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24.
16556440	Gillard M, Chatelain P, Fuks B: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10.
17431542	Newton HB, Dalton J, Goldlust S, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol. 2007 Sep;84(3):293-6. Epub 2007 Apr 13.
17461889	De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56.
18072813	Johannessen Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SV2A

# Drug_Target_1_GenBank_ID_Gene:
AB018279

# Drug_Target_1_GenBank_ID_Protein:
40788343

# Drug_Target_1_GeneCard_ID:
SV2A

# Drug_Target_1_Gene_Name:
SV2A

# Drug_Target_1_Gene_Sequence:
>2247 bp
AGTGCCCCAAGCCCCATCATGGAAGAGGGCTTCCGAGACCGGGCAGCTTTCATCCGTGGG
GCCAAAGACATTGCTAAGGAAGTCAAAAAGCATGCGGCCAAGAAGGTGGTGAAGGGCCTG
GACAGAGTCCAGGACGAATATTCCCGAAGATCGTACTCCCGCTTTGAGGAGGAGGATGAT
GATGATGACTTCCCTGCTCCCAGTGATGGTTATTACCGAGGAGAAGGGACCCAGGATGAG
GAGGAAGGTGGTGCATCCAGTGATGCTACTGAGGGCCATGACGAGGATGATGAGATCTAT
GAAGGGGAATATCAGGGCATTCCCCGGGCAGAGTCTGGGGGCAAAGGCGAGCGGATGGCA
GATGGGGCGCCCCTGGCTGGAGTAAGGGGGGGCTTGAGTGATGGGGAGGGTCCCCCTGGG
GGCCGGGGGGAGGCACAACGACGGAAAGAACGAGAAGAACTGGCCCAACAGTATGAAGCC
ATCCTACGGGAGTGTGGCCACGGCCGCTTCCAGTGGACACTGTATTTTGTGCTTGGTCTG
GCGCTGATGGCTGACGGTGTGGAGGTCTTTGTGGTGGGCTTCGTGCTGCCCAGCGCTGAG
AAAGACATGTGCCTGTCCGACTCCAACAAAGGCATGCTAGGCCTCATCGTCTACCTGGGC
ATGATGGTGGGAGCCTTCCTCTGGGGAGGTCTGGCTGACCGGCTGGGTCGGAGGCAGTGT
CTGCTCATCTCGCTCTCAGTCAACAGCGTCTTCGCCTTCTTCTCATCTTTTGTCCAGGGT
TACGGCACTTTCCTCTTCTGCCGCCTACTTTCTGGGGTTGGGATTGGAGGGTCCATCCCC
ATTGTCTTCTCCTATTTCTCCGAGTTTCTGGCCCAGGAGAAACGAGGGGAGCATTTGAGC
TGGCTCTGCATGTTTTGGATGATTGGTGGCGTGTACGCAGCTGCTATGGCCTGGGCCATC
ATCCCCCACTATGGGTGGAGTTTTCAGATGGGTTCTGCCTACCAGTTCCACAGCTGGAGG
GTCTTCGTCCTCGTCTGCGCCTTTCCTTCTGTGTTTGCCATTGGGGCTCTGACCACGCAG
CCTGAGAGCCCCCGTTTCTTCCTAGAGAATGGAAAGCATGATGAGGCCTGGATGGTGCTG
AAGCAGGTCCATGATACCAACATGCGAGCCAAAGGACATCCTGAGCGAGTGTTCTCAGTA
ACCCACATTAAGACGATTCATCAGGAGGATGAATTGATTGAGATCCAGTCGGACACAGGG
ACCTGGTACCAGCGCTGGGGGGTCCGGGCCTTGAGCCTAGGGGGGCAGGTTTGGGGGAAT
TTTCTCTCCTGTTTTGGTCCCGAATATCGGCGCATCACTCTGATGATGATGGGTGTGTGG
TTCACCATGTCATTCAGCTACTATGGCCTGACCGTCTGGTTTCCTGACATGATCCGCCAT
CTCCAGGCAGTGGACTACGCATCCCGCACCAAAGTGTTCCCCGGGGAGCGCGTAGAGCAT
GTAACTTTTAACTTCACGTTGGAGAATCAGATCCACCGAGGCGGGCAGTACTTCAATGAC
AAGTTCATTGGGCTGCGGCTCAAGTCAGTGTCCTTTGAGGATTCCCTGTTTGAAGAGTGT
TATTTTGAGGATGTCACATCCAGCAACACGTTTTTCCGCAACTGCACATTCATCAACACT
GTGTTCTATAACACTGACCTGTTCGAGTACAAGTTTGTGAACAGCCGTCTGATAAACAGT
ACATTCCTGCACAACAAGGAGGGCTGCCCGCTAGACGTGACAGGGACGGGCGAAGGTGCC
TACATGGTATACTTTGTGAGCTTCCTGGGGACACTGGCAGTGCTTCCTGGGAATATCGTG
TCTGCCCTGCTCATGGACAAGATCGGCAGGCTCAGAATGCTTGCTGGCTCCAGCGTGATG
TCCTGTGTCTCCTGCTTCTTCCTGTCTTTTGGGAACAGTGAGTCGGCCATGATCGCTCTG
CTCTGCCTTTTTGGCGGGGTCAGCATTGCATCCTGGAATGCGCTGGACGTGTTGACTGTT
GAACTCTACCCCTCAGACAAGAGGACCACAGCTTTTGGCTTCCTGAATGCCCTGTGTAAG
CTGGCAGCTGTGCTGGGGATCAGCATCTTCACATCCTTCGTGGGAATCACCAAGGCTGCA
CCCATCCTCTTTGCCTCAGCTGCCCTTGCCCTTGGCAGCTCTCTGGCCCTGAAGCTGCCT
GAGACCCGGGGGCAGGTGCTGCAGTGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
9872452	Nagase T, Ishikawa K, Suyama M, Kikuno R, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1998 Oct 30;5(5):277-86.

# Drug_Target_1_HGNC_ID:
HGNC:20566

# Drug_Target_1_HPRD_ID:
08922

# Drug_Target_1_ID:
1435

# Drug_Target_1_Locus:
1q21.2

# Drug_Target_1_Molecular_Weight:
82696

# Drug_Target_1_Name:
Synaptic vesicle glycoprotein 2A

# Drug_Target_1_Number_of_Residues:
742

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07690	MFS_1

# Drug_Target_1_Protein_Sequence:
>Synaptic vesicle glycoprotein 2A
MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPA
PSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLA
GVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADG
VEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLS
VNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFW
MIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRF
FLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRW
GVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDY
ASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVT
SSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFV
SFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGG
VSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFAS
AALALGSSLALKLPETRGQVLQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles

# Drug_Target_1_SwissProt_ID:
Q7L0J3

# Drug_Target_1_SwissProt_Name:
SV2A_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
5.26

# Drug_Target_1_Transmembrane_Regions:
170-190
206-226
234-254
263-283
295-315
335-355
448-468
599-619
627-647
652-672
686-708
713-731

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11879381	Lukyanetz EA, Shkryl VM, Kostyuk PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002 Jan;43(1):9-18.
17461889	De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CACNA1B

# Drug_Target_2_GenBank_ID_Gene:
M94172

# Drug_Target_2_GenBank_ID_Protein:
179758

# Drug_Target_2_GeneCard_ID:
CACNA1B

# Drug_Target_2_Gene_Name:
CACNA1B

# Drug_Target_2_Gene_Sequence:
>7020 bp
ATGGTCCGCTTCGGGGACGAGCTGGGCGGCCGCTATGGAGGCCCCGGCGGCGGAGAGCGG
GCCCGGGGCGGCGGGGCCGGCGGGGCGGGGGGCCCGGGTCCCGGGGGGCTGCAGCCCGGC
CAGCGGGTCCTCTACAAGCAATCGATCGCGCAGCGCGCGCGGACCATGGCGCTGTACAAC
CCCATCCCGGTCAAGCAGAACTGCTTCACCGTCAACCGCTCGCTCTTCGTCTTCAGCGAG
GACAACGTCGTCCGCAAATACGCGAAGCGCATCACCGAGTGGCCTCCATTCGAGTATATG
ATCCTGGCCACCATCATCGCCAACTGCATCGTGCTGGCCCTGGAGCAGCACCTCCCTGAT
GGGGACAAAACGCCCATGTCCGAGCGGCTGGACGACACGGAGCCCTATTTCATCGGGATC
TTTTGCTTCGAGGCAGGGATCAAAATCATCGCTCTGGGCTTTGTCTTCCACAAGGGCTCT
TACCTGCGGAACGGCTGGAACGTCATGGACTTCGTGGTCGTCCTCACAGGGATCCTTGCC
ACGGCTGGAACTGACTTCGACCTGCGAACACTGAGGGCTGTGCGTGTGCTGAGGCCCCTG
AAGCTGGTGTCTGGGATTCCAAGTTTGCAGGTGGTGCTCAAGTCCATCATGAAGGCCATG
GTTCCACTCCTGCAGATTGGGCTGCTTCTCTTCTTTGCCATCCTCATGTTTGCCATCATT
GGCCTGGAGTTCTACATGGGCAAGTTCCACAAGGCCTGTTTCCCCAACAGCACAGATGCG
GAGCCCGTGGGTGACTTCCCCTGTGGCAAGGAGGCCCCAGCCCGGCTGTGCGAGGGCGAC
ACTGAGTGCCGGGAGTACTGGCCAGGACCCAACTTTGGCATCACCAACTTTGACAATATC
CTGTTTGCCATCTTGACGGTGTTCCAGTGCATCACCATGGAGGGCTGGACTGACATCCTC
TATAATACAAACGATGCGGCCGGCAACACCTGGAACTGGCTCTACTTCATCCCTCTCATC
ATCATCGGCTCCTTCTTCATGCTCAACCTGGTGCTGGGCGTGCTCTCGGGGGAGTTTGCC
AAGGAGCGAGAGAGGGTGGAGAACCGCCGCGCCTTCCTGAAGCTGCGCCGGCAGCAGCAG
ATCGAGCGAGAGCTCAACGGGTACCTGGAGTGGATCTTCAAGGCGGAGGAAGTCATGCTG
GCCGAGGAGGACAGGAATGCAGAGGAGAAGTCCCCTTTGGACGTGCTGAAGAGAGCGGCC
ACCAAGAAGAGCAGAAATGACCTGATCCACGCAGAGGAGGGAGAGGACCGGTTTGCAGAT
CTCTGTGCTGTTGGATCCCCCTTCGCCCGCGCCAGCCTCAAGAGCGGGAAGACAGAGAGC
TCGTCATACTTCCGGAGGAAGGAGAAGATGTTCCGGTTTTTTATCCGGCGCATGGTGAAG
GCTCAGAGCTTCTACTGGGTGGTGCTGTGCGTGGTGGCCCTGAACACACTGTGTGTGGCC
ATGGTGCATTACAACCAGCCGCGGCGGCTTACCACGACCCTGTATTTTGCAGAGTTTGTT
TTCCTGGGTCTCTTCCTCACAGAGATGTCCCTGAAGATGTATGGCCTGGGGCCCAGAAGC
TACTTCCGGTCCTCCTTCAACTGCTTCGACTTTGGGGTCATCGTGGGGAGCGTCTTTGAA
GTGGTCTGGGCGGCCATCAAGCCGGGAAGCTCCTTTGGGATCAGTGTGCTGCGGGCCCTC
CGCCTGCTGAGGATCTTCAAAGTCACGAAGTACTGGAGCTCCCTGCGGAACCTGGTGGTG
TCCCTGCTGAACTCCATGAAGTCCATCATCAGCCTGCTCTTCTTGCTCTTCCTGTTCATT
GTGGTCTTCGCCCTGCTGGGGATGCAGCTGTTTGGGGGACAGTTCAACTTCCAGGATGAG
ACTCCCACAACCAACTTCGACACCTTCCCTGCCGCCATCCTCACTGTCTTCCAGATCCTG
ACGGGAGAGGACTGGAATGCAGTGATGTATCACGGGATCGAATCGCAAGGCGGCGTCAGC
AAAGGCATGTTCTCGTCCTTTTACTTCATTGTCCTGACACTGTTCGGAAACTACACTCTG
CTGAATGTCTTTCTGGCCATCGCTGTGGACAACCTGGCCAACGCCCAAGAGCTGACCAAG
GATGAAGAGGAGATGGAAGAAGCAGCCAATCAGAAGCTTGCTCTGCAAAAGGCCAAAGAA
GTGGCTGAAGTCAGCCCCATGTCTGCCGCGAACATCTCCATCGCCGCCAGGCAGCAGAAC
TCGGCCAAGGCGCGCTCGGTGTGGGAGCAGCGGGCCAGCCAGCTACGGCTGCAGAACCTG
CGGGCCAGCTGCGAGGCGCTGTACAGCGAGATGGACCCCGAGGAGCGGCTGCGCTTCGCC
ACTACGCGCCACCTGCGGCCCGACATGAAGACGCACCTGGACCGGCCGCTGGTGGTGGAG
CTGGGCCGCGACGGCGCGCGGGGGCCCGTGGGAGGCAAAGCCCGACCTGAGGCTGCGGAG
GCCCCCGAGGGCGTCGACCCTCCGCGCAGGCACCACCGGCACCGCGACAAGGACAAGACC
CCCGCGGCGGGGGACCAGGACCGAGCAGAGGCCCCGAAGGCGGAGAGCGGGGAGCCCGGT
GCCCGGGAGGAGCGGCCGCGGCCGCACCGCAGCCACAGCAAGGAGGCCGCGGGGCCCCCG
GAGGCGCGGAGCGAGCGCGGCCGAGGCCCAGGCCCCGAGGGCGGCCGGCGGCACCACCGG
CGCGGCTCCCCGGAGGAGGCGGCCGAGCGGGAGCCCCGACGCCACCGCGCGCACCGGCAC
CAGGATCCGAGCAAGGAGTGCGCCGGCGCCAAGGGCGAGCGGCGCGCGCGGCACCGCGGC
GGCCCCCGAGCGGGGCCCCGGGAGGCGGAGAGCGGGGAGGAGCCGGCGCGGCGGCACCGG
GCCCGGCACAAGGCGCAGCCTGCTCACGAGGCTGTGGAGAAGGAGACCACGGAGAAGGAG
GCCACGGAGAAGGAGGCTGAGATAGTGGAAGCCGACAAGGAAAAGGAGCTCCGGAACCAC
CAGCCCCGGGAGCCACACTGTGACCTGGAGACCAGTGGGACTGTGACTGTGGGTCCCATG
CACACACTGCCCAGCACCTGTCTCCAGAAGGTGGAGGAACAGCCAGAGGATGCAGACAAT
CAGCGGAACGTCACTCGCATGGGCAGTCAGCCCCCAGACCCGAACACTATTGTACATATC
CCAGTGATGCTGACGGGCCCTCTTGGGGAAGCCACGGTCGTTCCCAGTGGTAACGTGGAC
CTGGAAAGCCAAGCAGAGGGGAAGAAGGAGGTGGAAGCGGATGACGTGATGAGGAGCGGC
CCCCGGCCTATCGTCCCATACAGCTCCATGTTCTGTTTAAGCCCCACCAACCTGCTCCGC
CGCTTCTGCCACTACATCGTGACCATGAGGTACTTCGAGGTGGTCATTCTCGTGGTCATC
GCCTTGAGCAGCATCGCCCTGGCTGCTGAGGACCCAGTGCGCACAGACTCGCCCAGGAAC
AACGCTCTGAAATACCTGGATTACATTTTCACTGGTGTCTTTACCTTTGAGATGGTGATA
AAGATGATCGACTTGGGACTGCTGCTTCACCCTGGAGCCTATTTCCGGGACTTGTGGAAC
ATTCTGGACTTCATTGTGGTCAGTGGCGCCCTGGTGGCGTTTGCTTTCTCAGGATCCAAA
GGGAAAGACATCAATACCATCAAGTCTCTGAGAGTCCTTCGTGTCCTGCGGCCCCTCAAG
ACCATCAAACGGCTGCCCAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCCCTGAAG
AATGTCCTCAACATCTTGATTGTCTACATGCTCTTCATGTTCATATTTGCCGTCATTGCG
GTGCAGCTCTTCAAAGGGAAGTTTTTCTACTGCACAGATGAATCCAAGGAGCTGGAGAGG
GACTGCAGGGGTCAGTATTTGGATTATGAGAAGGAGGAAGTGGAAGCTCAGCCCAGGCAG
TGGAAGAAATACGACTTTCACTACGACAATGTGCTCTGGGCTCTGCTGACGCTGTTCACA
GTGTCCACGGGAGAAGGCTGGCCCATGGTGCTGAAACACTCCGTGGATGCCACCTATGAG
GAGCAGGGTCCAAGCCCTGGGTACCGCATGGAGCTGTCCATCTTCTACGTGGTCTACTTT
GTGGTCTTTCCCTTCTTCTTCGTCAACATCTTTGTGGCTTTGATCATCATCACCTTCCAG
GAGCAGGGGGACAAGGTGATGTCTGAATGCAGCCTGGAGAAGAACGAGAGGGCTTGCATT
GACTTCGCCATCAGCGCCAAACCCCTGACACGGTACATGCCCCAAAACCGGCAGTCGTTC
CAGTATAAGACGTGGACATTTGTGGTCTCCCCGCCCTTTGAATACTTCATCATGGCCATG
ATAGCCCTCAACACTGTGGTGCTGATGATGAAGTTCTATGATGCACCCTATGAGTACGAG
CTGATGCTGAAATGCCTGAACATCGTGTTCACATCCATGTTCTCCATGGAATGCGTGCTG
AAGATCATCGCCTTTGGGGTGCTGAACTATTTCAGAGATGCCTGGAATGTCTTTGACTTT
GTCACTGTGTTGGGAAGTATTACTGATATTTTAGTAACAGAGATTGCGGAAACGAACAAT
TTCATCAACCTCAGCTTCCTCCGCCTCTTTCGAGCTGCGCGGCTGATCAAGCTGCTCCGC
CAGGGCTACACCATCCGCATCCTGCTGTGGACCTTTGTCCAGTCCTTCAAGGCCCTGCCC
TACGTGTGTCTGCTCATTGCCATGCTGTTCTTCATCTACGCCATCATCGGCATGCAGGTG
TTTGGGAATATTGCCCTGGATGATGACACCAGCATCAACCGCCACAACAACTTCCGGACG
TTTTTGCAAGCCCTGATGCTGCTGTTCAGGAGCGCCACGGGGGAGGCCTGGCACGAGATC
ATGCTGTCCTGCCTGAGCAACCAGGCCTGTGATGAGCAGGCCAATGCCACCGAGTGTGGA
AGTGACTTTGCCTACTTCTACTTCGTCTCCTTCATCTTCCTGTGCTCCTTTCTGATGTTG
AACCTCTTTGTGGCTGTGATCATGGACAATTTTGAGTACCTCACGCGGGACTCTTCCATC
CTAGGTCCTCACCACTTGGATGAGTTCATCCGGGTCTGGGCTGAATACGACCCGGCTGCG
TGTGGGCGCATCAGTTACAATGACATGTTTGAGATGCTGAAACACATGTCCCCGCCTCTG
GGGCTGGGGAAGAAATGCCCTGCTCGAGTTGCTTACAAGCGCCTGGTTCGCATGAACATG
CCCATCTCCAACGAGGACATGACTGTTCACTTCACGTCCACGCTGATGGCCCTCATCCGG
ACGGCACTGGAGATCAAGCTGGCCCCAGCTGGGACAAAGCAGCATCAGTGTGACGCGGAG
TTGAGGAAGGAGATTTCCGTTGTGTGGGCCAATCTGCCCCAGAAGACTTTGGACTTGCTG
GTACCACCCCATAAGCCTGATGAGATGACAGTGGGGAAGGTTTATGCAGCTCTGATGATA
TTTGACTTCTACAAGCAGAACAAAACCACCAGAGACCAGATGCAGCAGGCTCCTGGAGGC
CTCTCCCAGATGGGTCCTGTGTCCCTGTTCCACCCTCTGAAGGCCACCCTGGAGCAGACA
CAGCCGGCTGTGCTCCGAGGAGCCCGGGTTTTCCTTCGACAGAAGAGTTCCACCTCCCTC
AGCAATGGCGGGGCCATACAAAACCAAGAGAGTGGCATCAAAGAGTCTGTCTCCTGGGGC
ACTCAAAGGACCCAGGATGCACCCCATGAGGCCAGGCCACCCCTGGAGCGTGGCCACTCC
ACAGAGATCCCTGTGGGGCGGTCAGGAGCACTGGCTGTGGACGTTCAGATGCAGAGCATA
ACCCGGAGGGGCCCTGATGGGGAGCCCCAGCCTGGGCTGGAGAGCCAGGGTCGAGCGGCC
TCCATGCCCCGCCTTGCGGCCGAGACTCAGCCCGTCACAGATGCCAGCCCCATGAAGCGC
TCCATCTCCACGCTGGCCCAGCGGCCCCGTGGGACTCATCTTTGCAGCACCACCCCGGAC
CGCCCACCCCCTAGCCAGGCGTCGTCGCACCACCACCACCACCGCTGCCACCGCCGCAGG
GACAGGAAGCAGAGGTCCCTGGAGAAGGGGCCCAGCCTGTCTGCCGATATGGATGGCGCA
CCAAGCAGTGCTGTGGGGCCGGGGCTGCCCCCGGGAGAGGGGCCTACAGGCTGCCGGCGG
GAACGAGAGCGCCGGCAGGAGCGGGGCCGGTCCCAGGAGCGGAGGCAGCCCTCATCCTCC
TCCTCGGAGAAGCAGCGCTTCTACTCCTGCGACCGCTTTGGGGGCCGTGAGCCCCCGAAG
CCCAAGCCCTCCCTCAGCAGCCACCCAACGTCGCCAACAGCTGGCCAGGAGCCGGGACCC
CACCCACAGGGCAGTGGTTCCGTGAATGGGAGCCCCTTGCTGTCAACATCTGGTGCTAGC
ACCCCCGGCCGCGGTGGGCGGAGGCAGCTCCCCCAGACGCCCCTGACTCCCCGCCCCAGC
ATCACCTACAAGACGGCCAACTCCTCACCCATCCACTTCGCCGGGGCTCAGACCAGCCTC
CCTGCCTTCTCCCCAGGCCGGCTCAGCCGTGGGCTTTCCGAACACAACGCCCTGCTGCAG
AGAGACCCCCTCAGCCAGCCCCTGGCCCCTGGCTCTCGAATTGGCTCTGACCCTTACCTG
GGGCAGCGTCTGGACAGTGAGGCCTCTGTCCACGCCCTGCCTGAGGACACGCTCACTTTC
GAGGAGGCTGTGGCCACCAACTCGGGCCGCTCCTCCAGGACTTCCTACGTGTCCTCCCTG
ACCTCCCAGTCTCACCCTCTCCGCCGCGTGCCCAACGGTTACCACTGCACCCTGGGACTC
AGCTCGGGTGGCCGAGCACGGCACAGCTACCACCACCCTGACCAAGACCACTGGTGCTAG

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
1321501	Williams ME, Brust PF, Feldman DH, Patthi S, Simerson S, Maroufi A, McCue AF, Velicelebi G, Ellis SB, Harpold MM: Structure and functional expression of an omega-conotoxin-sensitive human N-type calcium channel. Science. 1992 Jul 17;257(5068):389-95.

# Drug_Target_2_HGNC_ID:
HGNC:1389

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3970

# Drug_Target_2_Locus:
9q34

# Drug_Target_2_Molecular_Weight:
262499

# Drug_Target_2_Name:
Voltage-dependent N-type calcium channel subunit alpha-1B

# Drug_Target_2_Number_of_Residues:
2339

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00520	Ion_trans

# Drug_Target_2_Protein_Sequence:
>Voltage-dependent N-type calcium channel subunit alpha-1B
MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYN
PIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPD
GDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWNVMDFVVVLTGILA
TAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAII
GLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNI
LFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFA
KERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAA
TKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVK
AQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRS
YFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVV
SLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQIL
TGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTK
DEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNL
RASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAE
APEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPP
EARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKECAGAKGERRARHRG
GPRAGPREAESGEEPARRHRARHKAQPAHEAVEKETTEKEATEKEAEIVEADKEKELRNH
QPREPHCDLETSGTVTVGPMHTLPSTCLQKVEEQPEDADNQRNVTRMGSQPPDPNTIVHI
PVMLTGPLGEATVVPSGNVDLESQAEGKKEVEADDVMRSGPRPIVPYSSMFCLSPTNLLR
RFCHYIVTMRYFEVVILVVIALSSIALAAEDPVRTDSPRNNALKYLDYIFTGVFTFEMVI
KMIDLGLLLHPGAYFRDLWNILDFIVVSGALVAFAFSGSKGKDINTIKSLRVLRVLRPLK
TIKRLPKLKAVFDCVVNSLKNVLNILIVYMLFMFIFAVIAVQLFKGKFFYCTDESKELER
DCRGQYLDYEKEEVEAQPRQWKKYDFHYDNVLWALLTLFTVSTGEGWPMVLKHSVDATYE
EQGPSPGYRMELSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKVMSECSLEKNERACI
DFAISAKPLTRYMPQNRQSFQYKTWTFVVSPPFEYFIMAMIALNTVVLMMKFYDAPYEYE
LMLKCLNIVFTSMFSMECVLKIIAFGVLNYFRDAWNVFDFVTVLGSITDILVTEIAETNN
FINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQV
FGNIALDDDTSINRHNNFRTFLQALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECG
SDFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFIRVWAEYDPAA
CGRISYNDMFEMLKHMSPPLGLGKKCPARVAYKRLVRMNMPISNEDMTVHFTSTLMALIR
TALEIKLAPAGTKQHQCDAELRKEISVVWANLPQKTLDLLVPPHKPDEMTVGKVYAALMI
FDFYKQNKTTRDQMQQAPGGLSQMGPVSLFHPLKATLEQTQPAVLRGARVFLRQKSSTSL
SNGGAIQNQESGIKESVSWGTQRTQDAPHEARPPLERGHSTEIPVGRSGALAVDVQMQSI
TRRGPDGEPQPGLESQGRAASMPRLAAETQPVTDASPMKRSISTLAQRPRGTHLCSTTPD
RPPPSQASSHHHHHRCHRRRDRKQRSLEKGPSLSADMDGAPSSAVGPGLPPGEGPTGCRR
ERERRQERGRSQERRQPSSSSSEKQRFYSCDRFGGREPPKPKPSLSSHPTSPTAGQEPGP
HPQGSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYKTANSSPIHFAGAQTSL
PAFSPGRLSRGLSEHNALLQRDPLSQPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTF
EEAVATNSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRARHSYHHPDQDHWC

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the "high-voltage activated" (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin- IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons

# Drug_Target_2_SwissProt_ID:
Q00975

# Drug_Target_2_SwissProt_Name:
CAC1B_HUMAN

# Drug_Target_2_Synonyms:
BIII
Brain calcium channel III
Calcium channel, L type, alpha-1 polypeptide isoform 5
Voltage- gated calcium channel subunit alpha Cav2.2

# Drug_Target_2_Theoretical_pI:
8.62

# Drug_Target_2_Transmembrane_Regions:
96-114
133-152
164-183
188-206
226-245
332-356
483-501
517-536
545-562
574-592
612-631
685-709
1152-1169
1186-1205
1218-1236
1247-1265
1285-1304
1392-1416
1472-1490
1506-1525
1534-1552
1564-1582
1602-1621
1684-1708

#END_DRUGCARD DB01202
